Wilson Parry, MD
Nephrology · Greenville, MSNPI 1124188347
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 247 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations.
Across 247 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Akebia Therapeutics Inc$719
- Nxstage Medical, Inc.$648
- Bayer$449
- Mallinckrodt Hospital Products Inc.$415
- Amgen$407
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,87698%
- Education$1242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 44 | $1,157 |
| Akebia Therapeutics Inc | 35 | $719 |
| Nxstage Medical, Inc. | 8 | $648 |
| Bayer | 26 | $449 |
| Mallinckrodt Hospital Products Inc. | 22 | $415 |
| Amgen | 20 | $407 |
| Fresenius USA Marketing, Inc. | 24 | $401 |
| Aurinia Pharma U.S., Inc. | 19 | $381 |
| Novo Nordisk | 7 | $251 |
| Vifor Pharma, Inc. | 7 | $164 |
| Ardelyx, Inc. | 8 | $150 |
| Boehringer Ingelheim | 7 | $125 |
| Melinta Therapeutics, LLC | 1 | $123 |
| ANI Pharmaceuticals, Inc. | 6 | $119 |
| Lundbeck LLC | 1 | $98 |
| GSK | 4 | $90 |
| Bard Peripheral Vascular, Inc. | 1 | $81 |
| Medtronic | 1 | $68 |
| Baxter Healthcare | 1 | $61 |
| Novartis | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NXSTAGE SYSTEM ONE$237
- RYBELSUS$125
- Baxdela$123
- System One$103
How this compares
$6,000 in reported general payments places this provider in the 85th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 281 | $767,704 |
| AuryxiaFerric Citrate | 100 | $198,157 |
| FarxigaDapagliflozin Propanediol | 197 | $141,923 |
| JardianceEmpagliflozin | 63 | $64,779 |
| Sevelamer Carbonate | 282 | $49,225 |
| RybelsusSemaglutide | 25 | $33,559 |
| KerendiaFinerenone | 14 | $16,874 |
| RenvelaSevelamer Carbonate | 19 | $15,801 |
| EntrestoSacubitril/Valsartan | 15 | $11,660 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $9,797 |
| Lanthanum Carbonate | 14 | $8,301 |
| Febuxostat | 42 | $3,063 |
| Labetalol Hcl | 30 | $1,871 |
| Calcium Acetate | 21 | $1,838 |
| Colchicine | 32 | $1,821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $401 | $767,704281 claims |
| Akebia Therapeutics IncAuryxia | $719 | $198,157100 claims |
| AstraZenecaFarxiga, Lokelma | $1,157 | $151,720212 claims |
| Boehringer IngelheimJardiance | $125 | $64,77963 claims |
| Novo NordiskRybelsus | $251 | $33,55925 claims |
| BayerKerendia | $449 | $16,87414 claims |
| NovartisEntresto | $56 | $11,66015 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $119 | $69127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Greenville
- Ravi PatelGreenville$4K
- Mohit AhujaFlowood$427K
- Padam HirachanNatchez$29K
- Brian RifkinHattiesburg$23K
- Otis GowdyMeridian$12K
- Richard MillerBrookhaven$10K
- Thomas WooldridgeTupelo$8K
- Steven WagnerFlowood$6K
- John Martin LeeTupelo$6K
- Francis PhillippiFlowood$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.